Tempus AI signals beyond the news: 67+ signals from 6 sources
The latest Tempus AI signal on this page is from Sep 29, 2026 (Patents): "TEMPUS AI, INC.'s patent output is accelerating: 24 grants in the past year, 3 in the past 30 days." The busiest sources: Glassdoor (15+), LinkedIn (15+) and Website changes (15+).
Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn
- Signals
- 67+
- Sources
- 6
- Last 90 days
- 38
- Latest
- Sep 29, 2026
Other signals · latest 10
Latest Tempus AI signals by source
67+ signals for Tempus AI across 6 sources.
Patents · Patent pace
TEMPUS AI, INC.'s patent output is accelerating: 24 grants in the past year, 3 in the past 30 days.
Over the past year TEMPUS AI, INC. received 24 US patent grants, concentrated in health tech / medical informatics and software / computing; the recent pace (11 in 90 days) is accelerating versus its trailing baseline.
- Grants, 12 months
- 24
- Grants, 90 days
- 11
- Grants, 30 days
- 3
- Pace
- Accelerating
Patents · Patent grant
Tempus AI was granted a patent for ECG-based heart disease detection.
In September 2026 Tempus AI patented a machine-learning system for assessing cardiovascular disease risk from ECGs and clinical records in healthcare settings.
- Patent title
- ECG-based cardiovascular disease detection systems and related methods
- Grant date
- Sep 15, 2026
- Inventors
- Alvaro E. Ulloa-Cerna, Noah Zimmerman, Greg Lee, Christopher M. Haggerty
- Tech area
- health tech / medical informatics
Glassdoor · Compensation dissatisfaction
Concerns raised about poor benefits including lack of 401k match
One former employee highlights poor benefits with no 401k match as a reason for talent loss, and another mentions compensation and benefits rating of 3 out of 5.
- Overall rating
- 3.1 of 5
- CEO approval
- 44%
- Reviews read
- 7
- Review window
- Aug 19, 2026 to Sep 6, 2026
Glassdoor · Strategic direction unclear
Company direction unclear with rapid, uncommunicated changes and shifting priorities
Reviews indicate a lack of clear vision, with leadership implementing rapid changes without input and a tendency for 'shiny objects' and changing priorities disrupting workflow.
- Overall rating
- 3.1 of 5
- CEO approval
- 44%
- Reviews read
- 7
- Review window
- Aug 19, 2026 to Sep 6, 2026
LinkedIn
Tempus CEO discusses unified stack for drug development with AI integration.
In a new article, our CEO of Data & Apps, Ryan Fukushima, shares his perspective on why drug development requires a unified stack • Proprietary Multimodal Data to capture actual biology • Tailored AI Models & Agents to perform multi-step scientific reasoning • High-Performance Compute brought directly to the data...
- Likes
- 47
- Comments
- 1
- Tags
- Artificial Intelligence, Product Development, Research & Development, Pharmaceuticals
- Initiatives
- integrating AI into drug development platform
LinkedIn
Tempus announces a webinar on advanced sequencing and data capabilities in the Japanese market.
Join us for a live #webinar on Tuesday, August 25, 2026 at 3:00 PM CT. Kara Werner and Nike Beaubier will join leaders from our joint venture with SoftBank to explore our advanced sequencing and data capabilities in the Japanese market. This webinar will provide an inside look at our Japan-based laboratory, our...
- Likes
- 66
- Comments
- 1
- Tags
- Data Management, Healthcare Technology, Medical Research
- Initiatives
- explore advanced sequencing and data capabilities in Japan
Product reviews · Missing features
SREs report Tempus lacks customization for dashboards, reporting, and workflow automation
Atharva S., an SRE at a mid-market company, expresses a need for more customization for dashboards, reporting, and workflow automation. A Verified User from a mid-market internet company also desires more customization options for dashboards and data visualizations.
- Star rating
- 4.5 of 5
- Reviewer
- Atharva S.
Product reviews · Usability issues
SREs report new users take time to learn Tempus' advanced features and workflows
Atharva S., an SRE at a mid-market company, reports that while Tempus is powerful, advanced features take time to learn and additional onboarding resources are needed. A Verified User from a mid-market internet company also notes that new users need time to get comfortable with the platform's workflows and...
- Star rating
- 4.5 of 5
- Reviewer
- Atharva S.
YouTube
Tempus AI 60% Rocket! Buy TEM Stock Now! TEM Stock Analysis
Ez Money Show analyzes Tempus AI stock, discussing its potential as a portfolio investment.
- Channel
- Ez Money Show
- Views
- 23
- Comments
- 0
- Tags
- Stock Analysis, Biotechnology, Precision Medicine
Website changes · Product launch
No new products, services, or major feature launches are indicated in the recent website update.
The content remains focused on existing solutions, clinical data, and integration capabilities without mention of new offerings.
- Page
- /oncology
Showing 10 of 67+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Tempus AI with the Signal API
One POST /v1/companies/enrich call with tempus.com returns Tempus AI signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "tempus.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Same industry
Other signals at related companies
Questions about Tempus AI other signals
What signals does Autobound track for Tempus AI besides news and filings?
What are people saying about Tempus AI online?
What do employees say about working at Tempus AI?
Has Tempus AI been granted patents recently?
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .